• Chia-Jui Yen, Naomi Kiyota, Nobuhiro Hanai, Shunji Takahashi, Tomoya Yokota, Shigemichi Iwae, Yasushi Shimizu, Ruey-Long Hong, Masahiro Goto, Jin-Hyoung Kang, LiWing Sum KennethWSKDepartment of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong, China., Robert L Ferris, Maura Gillison, Toshimitsu Endo, Vijayvel Jayaprakash, and Makoto Tahara.
• Division of Hematology and Oncology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
• Head Neck. 2020 Oct 1; 42 (10): 2852-2862.

BackgroundThe present study evaluated the 2-year survival of the Asian population in the CheckMate 141 trial.MethodsThe CheckMate 141 trial included patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). In the present study, 34 Asian patients (nivolumab group: 23 patients; investigator's choice of therapy [IC] group: 11 patients) were analyzed.ResultsThe median overall survival (OS) was 12.1 and 6.2 months for the nivolumab and IC groups, respectively. The estimated 2-year OS rates were 22.7% and 0% for the nivolumab and IC groups, respectively. In the nivolumab group, the patients with any treatment-related adverse events (TRAEs), including skin-related disorders, showed better OS than the patients without any TRAEs.ConclusionsNivolumab demonstrated prolonged OS benefits in the Asian population with platinum-refractory R/M SCCHN and a favorable safety profile. TRAEs, including skin-related disorders, may be favorable prognostic factors for nivolumab efficacy.Clinical Trial RegistrationNCT02105636.© 2020 The Authors. Head & Neck published by Wiley Periodicals LLC.

14 keywords...

hide…